Select your Market

Our R&D Approach

Our research mission is simple: innovations that improve the quality of life of people everywhere. That motivation keeps us at the forefront of the Healthcare, Life Science and Electronics industries.

Healthcare R&D

Our research scientists are working tirelessly to develop groundbreaking medicines and technologies to treat everything from cancer and multiple sclerosis to infertility. Wherever there is a medical need, our highly experienced research and development team hopes to meet it. Learn more

Life Science R&D

R&D focus: Reimagining new ways to meet the needs of our customers

Innovation is at the core of the value that we deliver to our customers. Our Life Science scientists and engineers tirelessly work to develop novel approaches to new and age-old challenges.We show our commitment to innovation through our financial investments as well. Every year, we invest around €400 million in R&D, supporting new innovations designed to meet our customers' most unmet needs – from antibodies to water purification systems. Innovation is visible when new products hit the shelves and when new services emerge. 

The ability to innovate is the core of our culture across all three of our businesses; Process Solutions, Advanced Solutions and Discover Solutions. Learn more

Electronics R&D

R&D focus: Keeping the world’s Electronics on the cutting edge

Our Electronics business is an innovation leader, constantly producing new technologies and new markets for our customers, often through partnerships across industries. We have come up with groundbreaking liquid crystal displays and windows, effect pigments for coatings and color cosmetics and high-tech materials for use in integrated circuits. Learn more

Related News

View All News
  1. Press Releases

    2026 Future Insight Prize Goes to Spear’s Vasilis Ntziachristos

    The € 300,000 research grant award recognizes Ntziachristos’ pioneering work in enabling non-invasive and continuous monitoring of human biology.

    2026/06/23

  2. Information

    AGM: Beckmann to be appointed as CEO May 1

    Belén Garijo passed symbolically the baton to Kai Beckmann. Annual General Meeting approved dividend of € 2.20.

    2026/04/24

  3. Press Releases

    MilliporeSigma Launches First Bio-Based Solvent Portfolio for HPLC

    MilliporeSigma introduces the first bio-based solvent portfolio for HPLC – renewable feedstocks, proven chromatography performance and lower CO2e.

    2026/04/21